Drug Information

General Information
Drug ID
DR01164
Drug Name
Midodrine
Synonyms
(+-)-1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; (+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide monohydrochloride; (+-)-Midodrine hydrochloride; (+/-)-1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; (-)-Midodrin hydrochloride; (-)-Midodrine hydrochloride; (RS)-N'-(beta-Hydroxy-2,5-dimethoxy-phenethyl)glycinamid; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol; 1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol hydrochloride; 1-(2,5-Dimethoxyphenyl)-2-glycinamidoethanol; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamid; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide; 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethylacetamide; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride; 2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hyyroxyethyl)acetamide monohydrochloride; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide; 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide hydrochloride; A 4020 Linz; A-4020 Linz; Acetamide, 2-amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)-, monohydrochloride; Acetamide, 2-amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)-, hydrochloride; Alphamine; Amatine; DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid; Gutron; Hipertan; MIDODRINE HYDROCHLORIDE; Metligene; Midamine; Midodrin; Midodrina; Midodrina [INN-Spanish]; Midodrine (INN); Midodrine HCL; Midodrine Monohydrochloride; Midodrine [BAN:INN]; Midodrine [INN:BAN]; Midodrine hydrochloride (JAN/USAN); Midodrine hydrochloride [USAN:JAN]; Midodrine hydrochloride [USAN]; Midodrinum; Midodrinum [INN-Latin]; N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]glycinamide; N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide; Pro-Amatine; Pro-Amatine (TN); ProAmatine; Proamatine (TN); ST-1085; St 1085; St. Peter 224; TS 701; [+/-]-1-[2,5-Dimethoxyphenyl]-2-glycinamidoethanol
Drug Type
Small molecular drug
Indication Prostate hyperplasia [ICD11:GA90] Approved [1]
Therapeutic Class
Vasoconstrictor Agents
Structure
3D MOL 2D MOL
Formula
C12H18N2O4
Canonical SMILES
COC1=CC(=C(C=C1)OC)C(CNC(=O)CN)O
InChI
InChI=1S/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)
InChIKey
PTKSEFOSCHHMPD-UHFFFAOYSA-N
CAS Number
CAS 133163-28-7
Pharmaceutical Properties Molecular Weight 254.28 Topological Polar Surface Area 93.8
Heavy Atom Count 18 Rotatable Bond Count 6
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
XLogP
-0.6
PubChem CID
4195
PubChem SID
10092 ,104305704 ,11336130 ,11361369 ,11364535 ,11367097 ,11369659 ,11372749 ,11373902 ,11377821 ,11462341 ,11466219 ,11467339 ,11485126 ,11485798 ,11489361 ,11491400 ,11492007 ,11495455 ,124963568 ,125684389 ,128965708 ,134222029 ,134337543 ,135002277 ,137240087 ,137248546 ,142173049 ,14847816 ,29223300 ,46507373 ,47365278 ,47365279 ,47662374 ,47736573 ,47810835 ,48035214 ,48259327 ,48416280 ,49698958 ,50064787 ,50122851 ,50122852 ,50949507 ,56464179 ,57322186 ,7433691 ,8152622 ,85788446 ,96024908
ChEBI ID
ChEBI:6933
TTD Drug ID
D02XJY
DT(s) Transporting This Drug PEPT1 Transporter Info Peptide transporter 1 Substrate [2]
References
1 Midodrine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.